The company is established as a leader in orphan drug therapies.

The drug Methoxyflurane is included to contribute to the effective and safe treatment of patients with acute, moderate, or severe pain.

Stendhal’s product portfolio continues to grow with the inclusion of Dimethyl Fumarate, the first oral treatment for multiple sclerosis. Also, incursions into molecules for advanced oncology therapies are initiated.

Commercial agreements are initiated to include innovative molecules for the cardiovascular area in the portfolio. The Cardiovascular Business Unit is formed and a molecule for arterial hypertension is launched. Stendhal becomes the first North American partner of Korea's pharma industry.

Stendhal is established as an undisputed leader in the treatment of HIV/AIDS and multiple sclerosis, with innovative treatments for critical care and genetic disorders. The product portfolio is strengthened by incorporating the first comprehensive treatment for HIV/AIDS in Mexico in the form of a tablet.

Stendhal ventures into Neurology by launching the first monoclonal antibody for the treatment of multiple sclerosis, leading to the creation of the Neurosciences Business Unit.

Creation of the Oncology Business Unit in a business alliance with Baxter.

Signing of the first commercial agreement with Gilead Sciences Inc. for anti-infective products. The remodeling of the manufacturing site is carried out, achieving high world-class standards in good practices for manufacturing, conditioning and storage, and product distribution and control.

Stendhal is born as a Pharmaceutical Laboratory.